A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population.

Jennifer S JewellJoshua BlackMatthew EllisHeather OlsenJanetta IwanickiRichard Dart

Published in: Clinical drug investigation (2023)

Drugs employing ADF technology may reduce the likelihood of tampering when compared to non-ADF formulations in a treatment-center population, which represents an opportunity for intervention in OUD among those still requiring pain management.

Keyphrases

pain management
chronic pain
randomized controlled trial
drug delivery
physical activity
intimate partner violence